Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q4 FY25 Earnings Presentation
30 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, May 19, 2025
Slide 1: Cover letter to stock exchanges
19th May 2025 IOLCP/CGC/2025 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai- 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Investor Presentation-
Slide 2: IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q4 & FY25
IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q4 & FY25
Slide 3: Q4 & FY25 Performance
Q4 & FY25 Performance
Slide 4: Business Updates
Business Updates • Commissioned Unit-11 for Paracetamol production at Barnala with an installed Commencement of capacity of 10,800 MTPA on 24th March 2025 New Paracetamol • The ₹155.51 crore investment, fully funded through internal accruals, enhances Unit (Unit-11) backward integration and scale. •
Slide 5: Q4 & FY25 Performance Highlights
Q4 & FY25 Performance Highlights Q4FY25 ₹ 527.8 Cr ₹ 67.5 Cr ₹ 31.6 Cr EBITDA Profit After Tax Revenue from Operations Margin 12.7% Margin 5.9% ₹ 2079.2 Cr ₹ 224.6 Cr ₹ 101.0 Cr FY25 EBITDA Profit After Tax Revenue from Operations Margin 10.7% Margin 4.8% Pharmaceuticals Chemicals Geographical Break
Slide 6: Standalone Profit & Loss Statement – Q4 & FY25
Standalone Profit & Loss Statement – Q4 & FY25 Particulars (in INR Cr.) Q4 FY25 Q4 FY24 Y-o-Y Q3 FY25 Q-o-Q FY25 FY24 Revenue from Operations 527.8 503.9 4.7% 523.3 0.9% 2079.2 2,132.8 Other Income 4.5 7.5 4.1 22.4 30.1 Total Revenue 532.3 511.4 4.1% 527.4 0.9% 2101.6 2,162.9 Cost of Materials Consu
Slide 7: Standalone Balance Sheet – FY25
Standalone Balance Sheet – FY25 Particulars (in INR Cr.) Mar 25 Mar 24 Particulars (in INR Cr.) Mar 25 Mar 24 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1,158.0 921.1 (i) Equity share capital 58.7 58.7 (ii) Right to Use Asset 0.0 0.0 (ii) Other equity 1
Slide 8: Standalone Cash Flow Statement– FY25
Standalone Cash Flow Statement– FY25 Particulars (in INR Cr.) Mar 25 Mar 24 Cash Flow from Operating Activities Profit before Tax 137.9 182.6 Adjustment for Non-Operating Items 79.8 59.8 Operating Profit before Working Capital Changes 217.7 242.4 Changes in Working Capital -20.7 90.1 Cash Generated
Slide 9: At a Glance
At a Glance
Slide 10: Journey So Far
Journey So Far 1986-91 1996-99 2000-07 2009-13 2015-16 2017-18 2019 - 20 2021-22 2023 2024 FY25 Incorporated & • 2000 - Commencement • 2015 - USFDA, EIR for • 2019 - Unit-06 for • Paracetamol capacity • Commencement established of Ibuprofen Unit-1 Ibuprofen Pantoprazole (Dedicated) has been increase
Slide 11: Business Overview
Business Overview Team size of 2900+ 2nd Largest producer Existing Facility: Zero Discharge Largest producer of employees of Iso Butyl Benzene Spanning 180+ acres Effluent Treatment Ibuprofen and the only (IBB) with ~30% Global Plant company worldwide being Expansion: Acquired 101 share backward int
Slide 12: Segment Overview- Pharmaceuticals
Segment Overview- Pharmaceuticals Largest global producer of Ibuprofen, with a ~30% World’s only company with full backward integration Commenced a fully backward-integrated Unit-11 market share and over 12,000 MT capacity for all Ibuprofen intermediates and KSMs for Paracetamol manufacturing at Bar
Slide 13: Segment Overview- Specialty Chemicals
Segment Overview- Specialty Chemicals Backward integration for 2nd Largest global Asia’s first continuous dual Ethyl Acetate Ibuprofen and Paracetamol REACH-certified for Ethyl manufacturer of Iso Butyl technology plant for MCA manufacturing capacity of by producing Acetic Acetate, enabling exports
Slide 14: Pharmaceuticals- A Key Focus
Pharmaceuticals- A Key Focus Expanding the non-Ibuprofen Business Installed Capacity Regulatory Filings* Therapeutic Area USDMF, CEP & ANVISA GMP Metformin Hydrochloride 7200 MTPA Anti-Diabetic Approved, China DMF Active 59% 58% USDMF, CEP & ANVISA GMP 57% Fenofibrate Multiproduct Plant Anti-Cholest
Slide 15: Manufacturing Facilities
Manufacturing Facilities API manufactured in batch manner and intermediates Facility is coupled with ISO class-8 HVAC system, PSA Dedicated and multiproduct blocks involved in & Specialty chemicals in continuous product delivery Nitrogen & Purified water along with 185 MTPH steam manufacturing of AP
Slide 16: Research & Development
Research & Development From Lab to Launch: 20 Products Commercialised, 8 More in the Making — R&D at the Heart of Our Growth Story 3 16 19 Patents DMF with USFDA CEP with EDQM A 120-member highly Working on generic skilled team, including 50+ molecules with latest DSIR approved facility for In-house
Slide 17: Certifications & Accreditations
Certifications & Accreditations Approved USFDA facility since EUGMP Certification in 2013, 2017 Certificate of Suitability Certified Halal in accordance with Certificate of DMF Registration ISO 9001:2015, 14001:2015 & 2015, recertified in 2019 & Recertification in 2020 from EDQM Shariah Board Guidel
Slide 18: Core Management Team
Core Management Team Varinder Gupta | (Managing Director) Wide and rich experience of more than 38 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence Vikas Gupta | (Joint Managing
Slide 19: Board of Directors
Board of Directors Rajender Mohan Malla Sharad Tyagi Harpal Singh Ms Rajni Jha (Chairman and Independent (Independent Director) (Independent Director) (Independent Director) Director) o With four decades of experience held o Over 38 years of intrapreneurship in o Over 37 year's experience of banking
Slide 20: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives • State of the art Zero liquid Discharge (ZLD) Facility • Committed to ensure that our operations have minimal impact on the environment Environment • Constantly monitoring environmental footprints and implementing relevant initiatives. • Conti
Slide 21: Industry Overview
Industry Overview
Slide 22: API Industry- Overview
API Industry- Overview Global API Market Size (In USD Bn) Indian API Market Size (In USD Bn) 4.40% 368.98 38.60 8.10% North America holds over 38% of India is the 3rd largest API the API market in 2024. 245.59 producer globally, contributing 8% Asia-Pacific—led by India and to the market, with over
Slide 23: Specialty Chemicals Industry- Overview
Specialty Chemicals Industry- Overview Global Spec. Chem Market Size Indian Spec. Chem Market Size Region wise Spec. Chem Market Size Growth (FY25-30) (In USD Bn) (In USD Bn) 3.23% 11% 3.80% 1054.70 92.60 7% 780.30 64.50 4% 3 3% 3% 2% 2024 2033 2024 2034 North Latin Europe Middle Japan China India A
Slide 24: Historical Performance
Historical Performance
Slide 25: Historical Standalone Performance
Historical Standalone Performance Revenues EBITDA & EBITDA % Cash Profit After Tax 13.0% 11.2% 12.1% 10.7% 2216 2243 2163 2102 288 209 208 252 262 189 185 225 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Segmental Revenue Cash Flow from Operations Capex Spent 1175 1259 1263 1212 290 2
Slide 26: Summary Statement of Standalone Profit and Loss
Summary Statement of Standalone Profit and Loss Particulars (in INR Cr.) FY25 FY24 FY23 FY22 Revenue from Operations 2079.2 2,132.8 2,217.1 2,184.0 Other Income 22.4 30.1 25.6 32.0 Total Revenue 2101.6 2,162.9 2,242.7 2,216.1 Cost of Materials Consumed 1358.3 1,435.1 1,536.1 1,578.9 Purchase of Trad
Slide 27: Summary Statement of Standalone Balance Sheet
Summary Statement of Standalone Balance Sheet Particulars (in INR Cr.) Mar 25 Mar 24 Mar 23 Mar 22 Particulars (in INR Cr.) Mar 25 Mar 24 Mar 23 Mar 22 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1,158.0 921.1 750.5 559.5 58.7 58.7 58.7 58.7 (i) Equity s
Slide 28: Summary Statement of Standalone Cashflow
Summary Statement of Standalone Cashflow Particulars (in INR Cr.) Mar 25 Mar 24 Mar 23 Mar 22 Cash Flow from Operating Activities Profit before Tax 137.9 182.6 189.5 222.8 Adjustment for Non-Operating Items 79.8 59.8 44.4 33.1 Operating Profit before Working Capital Changes 217.7 242.4 233.9 256.0 C
Slide 29: Way Forward
Way Forward Backward Integration for Margin Product Diversification Beyond Export Contribution to Rise Scaling Through Land Acquisition and Supply Chain Resilience Ibuprofen The non-Ibuprofen share in the pharmaceuticals segment has The company adopts a strategic The company has acquired 101 acres i
Slide 30: Thank You
COMPANY : IOL Chemicals and Pharmaceuticals Ltd. CIN : L24116PB1986PLC007030 Mr. Abhay Raj Singh - Sr. VP & Company Secretary investor@iolcp.com E-mail: investor@iolcp.com www.iolcp.com www.iolcp.com INVESTOR RELATIONS ADVISORS : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a
IOL Chemicals and Pharmaceuticals — Q4 FY25 Earnings Presentation on 6ix